Immune Response Affecting Drug Patents (Class 514/885)
-
Patent number: 5695753Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant. Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.Type: GrantFiled: June 6, 1995Date of Patent: December 9, 1997Assignee: Behringwerke AktiengesellschaftInventors: Thomas Stief, Norbert Heimburger, Hans Ulrich Schorlemmer
-
Patent number: 5693645Abstract: A method for treating inflammatory bowel disease in a mammal that includes administering to the mammal and effective amount of spiperone or a spiperone derivative or a pharamaceutically acceptable salt thereof.Type: GrantFiled: August 31, 1994Date of Patent: December 2, 1997Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Richard J. Sharpe, Kenneth A. Arndt, Stephen J. Galli, Peter C. Meltzer, Raj K. Razdan, Howard P. Sard
-
Patent number: 5686577Abstract: The present invention relates to an isolated protein or polypeptide capable of production by T cells and capable of ultimately activating production of B cells. The present invention further provides an isolated DNA molecule encoding the protein or polypeptide capable of production by T cells and capable of ultimately activating production of B cells. The isolated DNA molecule can be inserted as a heterologous DNA in an expression vector forming a recombinant DNA expression system for producing the protein or polypeptide. Likewise, the heterologous DNA can be incorporated in a cell to achieve this objective. The isolated protein or polypeptide of the present invention can be combined with a pharmaceutically-acceptable carrier or used alone for administration to mammals for activating production of B cells.Type: GrantFiled: October 17, 1994Date of Patent: November 11, 1997Assignee: Cornell Research Foundation, Inc.Inventors: Marc E. Weksler, Paul Szabo
-
Patent number: 5686467Abstract: A method of inhibiting imperfect tissue repair or a physiological condition due at least in part thereto comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: March 15, 1995Date of Patent: November 11, 1997Assignee: Eli Lilly and CompanyInventors: Thomas F. Bumol, George J. Cullinan
-
Patent number: 5683697Abstract: A pharmaceutical composition for treatment of AIDS comprising (1) herb medicines having anti-inflammatory anti-fever, expectorant or anti-tussive action, (2) herb medicines having nourishment, tonic, gastrointestinal tract function-improving or digestive action, and (3) herb medicines having anti-fungal or anti-viral action.Type: GrantFiled: October 6, 1995Date of Patent: November 4, 1997Inventor: Michio Tani
-
Patent number: 5683693Abstract: Methods for inducing T cell unresponsiveness to a tissue or organ graft in a transplant recipeint are disclosed. The methods involve administering to a subject: 1) an allogeneic or xenogeneic cell which expresses donor antigens and which has a ligand on the cell surface which interacts with a receptor on the surface of a recipient T cell which mediates contact-dependent helper effector function; and 2) an antagonist of the receptor which inhibits interaction of the ligand with the receptor. In a preferred embodiment, the allogeneic or xenogeneic cell is a B cell, preferably a resting B cell, and the molecule on the surface of the T cell which mediates contact-dependent helper effector function is gp39. A preferred gp39 antagonist is an anti-gp39 antibody. The allogeneic or xenogeneic cell and the gp39 antagonist are typically administered to a transplant recipient prior to transplantation of the tissue or organ.Type: GrantFiled: April 25, 1994Date of Patent: November 4, 1997Assignees: Trustees of Dartmouth College, University of Massachusetts Medical CenterInventors: Randolph J. Noelle, Fiona H. Durie, David C. Parker, Michael C. Appel, Nancy E. Phillips, John P. Mordes, Dale L. Grenier, Aldo A. Rossini
-
Patent number: 5681557Abstract: There is disclosed a method of treating microbial infections in microbially infected mammals and a method of augmenting antitumor immunotoxicity in a mammal comprising administering a therapeutically effective amount of IL-7 in a pharmaceutically acceptable carrier. There is further disclosed a method of stimulating macrophages to produce cytokines made by activated macrophages and a method for improving T cell presentation by a macrophage comprising administering a therapeutically effective amount of IL-7. Further, antimicrobial activity of macrophages can be improved by administering a combination of IL-7 and Interferon-.gamma..Type: GrantFiled: May 15, 1995Date of Patent: October 28, 1997Assignee: Sterling Winthrop Inc.Inventors: Kenneth H. Grabstein, Mark Alderson
-
Patent number: 5681571Abstract: An immunological tolerance-inducing agent comprising a mucosa-binding molecule linked to a specific tolerogen is disclosed. Further, a method of inducing immunological tolerance in an individual against a specific antigen, including hapten, which causes an unwanted immune response in said individual comprising administration by a mucosal route of an immunologically effective amount of an immunological tolerance-inducing agent of the invention to said individual, is described.Type: GrantFiled: January 19, 1994Date of Patent: October 28, 1997Assignee: Duotol ABInventors: Jan Holmgren, Cecil Czerkinsky
-
Patent number: 5679644Abstract: Triterpenoid acid derivatives are described that exhibit dual pharmacophobic activities, specifically selectin ligand and leukotriene biosynthetic inhibitory activities, and that thus have significant applications for the treatment or prevention of certain diseases including cancer and diseases associated with the inflammatory process as well as applications for the diagnosis of disease.Type: GrantFiled: June 6, 1995Date of Patent: October 21, 1997Assignee: Glycomed IncorporatedInventors: Narasinga Rao, Mark Brian Anderson, John Henry Musser
-
Patent number: 5679667Abstract: Aminoalcohols N-acyl derivatives useful in the prevention and in the treatment of mammalian pathologies induced by mast cell degranulation in consequence of peripheral nerve noxae.Type: GrantFiled: October 21, 1994Date of Patent: October 21, 1997Assignee: Lifegroup S.P.A.Inventors: Francesco Della Valle, Silvana Lorenzi, Federica Della Valle
-
Patent number: 5670143Abstract: The preferred oligomers of the present invention are polyureas, polycarbonates, polyesters or polyamides having a number average molecular weight of <10,000. These oligomers are water-soluble, have a rigid backbone, have recurring units coupled by carbonyl linking moieties which have anionic groups, display predominantly linear geomentry such that regular spacing between anionic groups exists in an aqueous medium, and are pharmaceutically-acceptable. The oligomers are useful for the treatment and/or diagnosis of AIDS and ARC.Type: GrantFiled: May 19, 1995Date of Patent: September 23, 1997Assignees: Merrell Pharmaceuticals Inc., The Dow Chemical CompanyInventors: Alan D. Cardin, Richard L. Jackson, Michael J. Mullins
-
Patent number: 5670478Abstract: Medical preparations (drugs) containing N-methylated cyclic undecapeptides, especially for internal use, characterized by the presence of 0.1 to 20 weight parts of compounds from the group of cyclosporins (A), 0.3 to 60 weight parts of emulsifier (B) containing anhydromanitol oleylether and/or lactoglyceride and/or citrogylceride, 0.1 to 10 weight parts of emulsion stabilizer (C) containing aluminium-magnesium hydroxy-stearate as a lipogel and 0.2 to 40 weight parts of a solvent (D) composed of 1,4: 3,6-dianhydro-2,5-di-O-methyl-D-glucitole and/or 1,3-dimethyl-2-imidazolidone and/or ethanol, with the ratio A:B being equal to 1:05-1:30.Type: GrantFiled: February 22, 1995Date of Patent: September 23, 1997Assignee: Galena, a.s.Inventors: Milan Stuchlik, Zdenek Pavelek, Lubos Markovic
-
Patent number: 5670520Abstract: A method for inhibiting nucleoside and nucleobase transport in mammalian cells, as well as to a method for inhibition of virus replication, and augmenting phosphorylation of nucleoside analogues, are disclosed, wherein each method uses, as the active agent, a carbostyril derivative.Type: GrantFiled: March 26, 1996Date of Patent: September 23, 1997Assignee: Otsuka Pharmaceutical Co., Ltd.Inventors: Erwin W. Gelfand, Naohiro Terada
-
Patent number: 5668115Abstract: An anti-inflammatory drug comprising as the effective component at least one compound selected from the group consisting of colominic acid, partial hydrolysis products of colominic acid and pharmaceutically acceptable salts thereof. The drug is used as a drug for renal diseases, a drug for hepatitis, an immunomodulator and a drug for inhibiting the chemotaxis of neutrophil.Type: GrantFiled: May 25, 1995Date of Patent: September 16, 1997Assignee: MECT CorporationInventors: Ryoichi Osawa, Isao Suda, Masaaki Numata, Mamoru Sugimoto, Kenkichi Tomita, Nobuyuki Kibushi, Takayuki Ishii, Naokazu Sugiyama, Makiko Kasano, Tae Yasunaga, Makoto Tanaka, Tomoya Ogawa, Mariko Ishii
-
Patent number: 5663209Abstract: The present invention reveals the isolation, purification and characterization from the creosote bush Larrea tridentata of compounds of the structural formula: ##STR1## where R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each selected from the group consisting of HO--, CH.sub.3 O-- and CH.sub.3 (C.dbd.O)O--, provided that R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are not each HO-- simultaneously. Each compound is a derivative of 1,4-bis-(3,4-dihydroxyphenyl)-2,3-dimethylbutane (nordihydroquaiaretic acid, NDGA). In addition, NDGA and each derivative can be used in a method to suppress Tat transactivation of a lentivirus, including the HIV virus, in a cell by administering NDGA or a derivative of NDGA to the cell.Type: GrantFiled: April 4, 1996Date of Patent: September 2, 1997Assignee: The Johns Hopkins UniversityInventors: Ru Chih C. Huang, John N. Gnabre
-
Patent number: 5660826Abstract: Methods and compositions are provided for the treatment or prophylaxis of systematic inflammatory response syndrome by administering an antagonist to parathyroid hormone-related protein, such as antibodies to PTHrP.Type: GrantFiled: June 6, 1995Date of Patent: August 26, 1997Assignee: The Regents of the University of CaliforniaInventors: Carl Grunfield, Janet Funk, Kenneth R. Feingold
-
Patent number: 5658955Abstract: This invention relates to the treatment of the immune disorders fibromyalgia and chronic fatigue syndrome with the combination of therapeutically effective amounts of a serotonin agonist and a dopamine agonist. In addition, a method of improving vector gene therapy with the combination of a serotonin agonist and a dopamine agonist is provided.Type: GrantFiled: November 1, 1995Date of Patent: August 19, 1997Inventor: Pietr Hitzig
-
Patent number: 5656469Abstract: A method for encapsulating biological substances in biocompatible microcapsules is disclosed, the method comprising:(a) maintaining a coating-forming liquid film sheet transverse to a vertical plane, said sheet comprising an organic polymerizable monomer liquid,(b) causing droplets comprising biological substances in an aqueous medium to fall downwardly through said liquid film sheet to form microcapsules comprising cores of said droplets coated by said film,(c) permitting said microcapsules to fall downwardly from said liquid film sheet, and(d) polymerizing said liquid film coatings during descent of said microcapsules below said sheet to form a permeable polymer coating of a sufficient structural integrity so that said microcapsules are self-supporting.Type: GrantFiled: August 14, 1995Date of Patent: August 12, 1997Assignee: Brown University Research FoundationInventors: Patrick A. Tresco, John F. Mills
-
Patent number: 5651980Abstract: The invention covers a method of implanting a living donor cell into a host animal without inflammatory response or rejection of the donor cell by the host animal, by obtaining an uncoated particle of a biocompatible, temperature-independent gel that encapsulates the living donor cell, wherein the uncoated particle provides a molecular weight cutoff that prevents host animal immune cells from entering the particle, yet does not have to prevent entry of host animal IgG and complement into the particle, and implanting the uncoated particle into the host animal.Type: GrantFiled: April 15, 1994Date of Patent: July 29, 1997Assignee: Biohybrid Technologies, Inc.Inventors: Robert P. Lanza, Willem M. Kuhtreiber, William L. Chick
-
Patent number: 5646128Abstract: Novel compounds which selectively inhibit adenosine kinase and methods of preparing adenosine kinase inhibitors are provided. Also provided are methods of treating various inflammatory conditions, including arthritis and SIRS, which may be ameliorated by increased local concentrations of adenosine using adenosine kinase inhibitors.Type: GrantFiled: December 1, 1994Date of Patent: July 8, 1997Assignee: Gensia, Inc.Inventors: Gary S. Firestein, Bheemarao G. Ugarkar, Leonard P. Miller, Harry E. Gruber, David A. Bullough, Mark D. Erion, Angelo J. Castellino, Clinton E. Browne
-
Patent number: 5646123Abstract: Disclosed are methods for reducing the degree of antigen induced inflammation in a sensitized mammals. The disclosed methods employ oligosaccharide glycosides related to blood group determinants having a type I or type II core structure wherein the administration of such oligosaccharide glycosides is after initiation of the mammal's immune response but at or prior one-half the period of time required to effect maximal antigen-induced inflammation.Type: GrantFiled: March 17, 1995Date of Patent: July 8, 1997Assignee: Alberta Research CouncilInventors: Robert M. Ippolito, Wasimul Haque, Cong Jiang, H. Rizk Hanna, Andre P. Venot, Pandurang V. Nikrad, Mohammed A. Kashem, Richard Smith, Om P. Srivastava
-
Patent number: 5646130Abstract: An oligosaccharide containing about 20 monosaccharide units is provided. This oligosaccharide designated (M.sub.9 G).sub.2 is a copolymer .beta.-D-(1.fwdarw.4) connected mannuronopyranose units and an .alpha.-L-(1.fwdarw.4) connected guluronic acid unit at a ratio of 9:1. In addition, 40-60% of the carboxylic functional groups are esterified with propanol, 2-propanol or methanol, and substantially all of the C.sub.2 carbons and about 50% of the C.sub.3 positions of the residues are sulfated, such that the resulting compound contains about 7-13% organic sulfur. The compounds are used for the prevention and therapy of thrombosis-induced ischemic vascular diseases of the heart and the central nervous system, for treating acute thrombosis-induced brain infarction and in coronary ischemia-induced angina, and for treating hyperlipoproteinemia and lowering the relative amount of cholesterol.Type: GrantFiled: June 30, 1995Date of Patent: July 8, 1997Assignee: Ocean University of OingdaoInventor: Guan Hua Shi
-
Patent number: 5643565Abstract: Methods for enhancing the immune response to vaccination in animals, including humans, comprise administering interleukin-2 (IL-2) as part of the vaccination regimen, preferably for 5 to 14 days post-vaccination. In addition, compositions for enhancing the immune response of an animal to a vaccine employ IL-2 as an active ingredient, preferably human IL-2.Type: GrantFiled: May 24, 1995Date of Patent: July 1, 1997Assignee: Chiron CorporationInventors: Michael V. Doyle, Arthur D. Newell, Jack H. Nunberg, Thomas J. White
-
Patent number: 5639758Abstract: A method for the treatment of a cutaneous, ocular, or mucosal pathological condition which is associated with immune response in a human or other mammal, that includes topical application of an effective amount of spiperone or a spiperone derivative or its pharmaceutically acceptable salt, in a pharmaceutically-acceptable diluent or carrier for topical application.Type: GrantFiled: September 13, 1993Date of Patent: June 17, 1997Assignee: Beth Israel Deaconess Medical Center, Inc.Inventors: Richard J. Sharpe, Kenneth A. Arndt, Stephen J. Galli
-
Patent number: 5639453Abstract: A method of treating leukopenia, by administering an IL-3 polypeptide, is disclosed.Type: GrantFiled: January 10, 1995Date of Patent: June 17, 1997Assignee: Genetics Institute, Inc.Inventors: Steven C. Clark, Agnes B. Ciarletta, Yu-Chung Yang
-
Patent number: 5639474Abstract: The present invention relates to a microemulsion concentrate containing cyclosporin as an active ingredient, dimethylisosorbide as a cosurfactant, oil and a surfactant which is suitable for the formulation of a soft capsule for oral administration, said cyclosporin, dimethyl isosorbide, oil and surfactant being present in the ratio of 1:1-5:1-5:2-10, and preferably in the ratio of 1:2-4:2-5:2-4:7, by weight. Since dimethylisosorbide has substantially no membrane permeation property, the soft capsule preparation according to the present invention is outstandingly stable in comparison with the soft capsules containing ethanol, propylene glycol, transcutol, glycofurol, etc., as a cosurfactant in the prior art, and further provides an advantage in that the pharmaceutical effect, appearance and composition content of the soft capsule according to the present invention are not changed.Type: GrantFiled: April 24, 1995Date of Patent: June 17, 1997Assignee: Hanmi Pharm. Ind., Ltd.Inventor: Jong Soo Woo
-
Patent number: 5637563Abstract: A method for making and identifying mistletoe extracts as being of a pharmaceutical grade which is useful in treating AIDS, cancers and other diseases where the immune system is suppressed. The method is based on the discovery of five marker proteins which selectively bind with different sugars. Pharmaceutical grade extracts in accordance with the invention require certain concentration levels of each protein. An additional further requirement is that each protein fraction must meet specific bioactivity levels with respect to preventing malignant cell proliferation. Fingerprint markers with respect to viscotoxins and alkaloids present in the extract are also provided. Methods of treatment using the pharmaceutical grade mistletoe are disclosed.Type: GrantFiled: April 14, 1995Date of Patent: June 10, 1997Assignee: University of Southern CaliforniaInventor: Tasneem A. Khwaja
-
Patent number: 5635175Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.Type: GrantFiled: January 11, 1995Date of Patent: June 3, 1997Assignee: Chiron CorporationInventors: Peter Ralph, Kong T. Chong
-
Patent number: 5632980Abstract: AIDS therapeutic agents are provided which are less toxic, have a strong anti-AIDS virus activity and comprise as an effective ingredient a dehydrogenation polymer of a cinnamic acid derivative having a phenyl group substituted with at least one hydroxyl group or a pharmaceutically acceptable salt thereof.Type: GrantFiled: November 27, 1992Date of Patent: May 27, 1997Inventors: Kunio Konno, Hiroshi Sakagami, Yutaka Kawazoe, Naoki Yamamoto
-
Patent number: 5631245Abstract: Adverse inflammatory reactions can be treated by administrating to an organism a composition having diglucosylamine as the active ingredient. The preferred compound is di-Beta-D-glucopyranosylamine. A simple method for making diglucosylamine in high purity is obtained by reacting glucose, a nitrogen containing base, and either methanol or ethanol to form the diglucosylamine and then recovering the diglucosylamine preferably with the use of charcoal. The preferred diglucosylamine, di-Beta-D-glucopyranosylamine, has extraordinary anti-inflammatory activity. It can be formulated with a pharmaceutically acceptable carrier to make pharmaceutical compositions which are effective in treating inflammations. This pharmaceutical composition can also be used to treat adverse inflammatory reactions that are the result of the disruptions of a dynamic network of cellular mechanisms in organisms.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Assignee: Biodynamics Pharmaceuticals, Inc.Inventor: Clairmont G. Drube
-
Patent number: 5631001Abstract: A ground mixture (80:20 by weight) of dried grapefruit seeds and grapefruit pulp respectively is subjected to extraction using an equal amount by weight of glycerin. The resulting extract is an effective bactericide, fungicide, and virucide, and is expected to be particularly effective in the treatment of HIV infections.Type: GrantFiled: June 6, 1995Date of Patent: May 20, 1997Inventors: Jakob Harich, Elizabeth K. Harich, administratrix
-
Patent number: 5626845Abstract: Materials immunoreactive with parathyroid hormone-related protein (PTH-rp) are used in the invention method to prevent and treat metastasis and cancer cell growth in bone as well as osteolysis and symptomatic sequelae thereof. Humanized antibodies are included in the invention for application of the invention method to human subjects.Type: GrantFiled: January 23, 1995Date of Patent: May 6, 1997Assignee: Xenotech IncorporatedInventors: Toshiyuki Yoneda, Gregory R. Mundy
-
Patent number: 5627185Abstract: Derivatives of Acyclovir are provided having patent antiviral inhibitory activity. Phosphotriester derviatives are preferred which have the structure: ##STR1## where R is alkyl, especially CH.sub.3 or (CH.sub.3).sub.3 C.Type: GrantFiled: June 5, 1995Date of Patent: May 6, 1997Inventors: Gilles Gosselin, Jean-Louis Imbach
-
Patent number: 5627160Abstract: The present invention relates to the surprising discovery that certain dideoxynucleoside analogs which contain a dideoxy ribofuranosyl moiety having an L-configuration (as opposed to the naturally occurring D-configuration) exhibit unexpected activity against Hepatitis B virus (HBV). In particular, the compounds according to the present invention show potent inhibition of the replication of the virus in combination with very low toxicity to the host cells (i.e., animal or human tissue). Compounds according to the present invention exhibit primary utility as agents for inhibiting the growth or replication of HBV, HIV and other retroviruses, most preferably HBV. The compound 1-(2,3-dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine is shown to be a potent anti-HIV agent with low toxicity to host cells.Type: GrantFiled: July 28, 1993Date of Patent: May 6, 1997Assignee: Yale UniversityInventors: Tai-Shun Lin, Yung-Chi Cheng
-
Patent number: 5624938Abstract: This invention provides a pharmaceutical composition which comprises an amount of chloroquine effective to block MHC Class I recycling and an amount of a CD8+ T cell stimulatory agent effective to stimulate proliferation of CD8+ T cells to a concentration such that the resulting CD8+ T cells kill CD4+ T cells, and a pharmaceutically acceptable carrier.This invention provides a method for treating an autoimmune disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the autoimmune disease.This invention provides a method for treating cutaneous lymphoma disease in a subject which comprises administering to the subject an amount of chloroquine effective to treat the cutaneous lymphoma disease.This invention provides a method for treating rheumatoid arthritis in a subject which comprises administering to the subject an amount of the pharmaceutical composition of chloroquine and a CD8+ T cell stimulatory agent effective to treat rheumatoid arthritis.Type: GrantFiled: July 18, 1994Date of Patent: April 29, 1997Assignee: The Trustees of Columbia University in the City of New YorkInventor: Benvenuto G. Pernis
-
Patent number: 5622940Abstract: Methods of treating or preventing infection-induced oral tissue destruction or gingivitis in a mammal, comprising administering a therapeutically effective amount of a .beta.(1,3)-glucan, such as poly-.beta.(1-6)-glucotriosyl-.beta.(1-3)-glucopyranose glucan (PGG-glucan), are disclosed.Type: GrantFiled: July 14, 1994Date of Patent: April 22, 1997Assignee: Alpha-Beta TechnologyInventor: Gary R. Ostroff
-
Patent number: 5620703Abstract: A process for stimulating hematopoietic activity in animals which comprises administering to a patient in need therefor a therapeutically effective amount of an agent containing as its active ingredient a water-soluble or lipid-soluble transition metal compound in a lyotropic mesophase, the agent optionally containing one or more additional carriers for stimulating hematopoietic activity.Type: GrantFiled: March 31, 1994Date of Patent: April 15, 1997Assignee: Max-Delbruck-Centrum Fur Molekulare MedizinInventors: Regina Reszka, Iduna Fichtner
-
Patent number: 5618557Abstract: Methods and devices for preventing an adverse reaction of the skin to the presence of a skin-sensitizing agent by administering an effective amount of a potassium-sparing diuretic.Type: GrantFiled: November 22, 1994Date of Patent: April 8, 1997Assignee: E.R. Squibb & Sons, Inc.Inventors: John J. Wille, Agis Kydonieus, Frank S. Castellana
-
Patent number: 5614183Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in treating or preventing bacterial, viral or fungal infections, neoplasms, leukopenia, wounds, and in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein.Type: GrantFiled: January 11, 1995Date of Patent: March 25, 1997Assignee: Chiron CorporationInventors: Peter Ralph, Kong T. Chong
-
Patent number: 5612319Abstract: A method of preventing the establishment of HIV infection and/or HIV seroconversion in a human or simian comprising the administration of an effective amount of the compound 1-[2',3'-dideoxy-3'C-(hydroxymethyl)-.beta.-D-erythropentofuranosyl]-cytos ine having the following formula: ##STR1## or a pharmaceutically acceptable salt thereof, after exposure of said human or simian to HIV.Type: GrantFiled: May 31, 1994Date of Patent: March 18, 1997Assignee: Medivir ABInventor: Bo F. Oberg
-
Patent number: 5607673Abstract: In HIV infected individuals, certain clinical and biological markers are used to assess the progression or regression of the disease. From the plant, Uvaria bevistipitata of the Annonaceae family, a substantially pure extract was derived. This extract was administered to 268 HIV infected patients in a clinical trail in Zaire Africa and dramatic results were obtained. The extract was also submitted to a laboratory for in vitro analysis. when tested against the HIV reverse transcriptase enzyme, the extract tested 96.7% active. In further laboratory analysis, against HIV-.sub.IIB, it demonstrated efficacy at doses that showed no cytotoxic effects.Type: GrantFiled: April 20, 1995Date of Patent: March 4, 1997Assignee: C.S.S.A.H.A., Inc.Inventor: Constantin M. Bashengezi
-
Patent number: 5603937Abstract: An immune-enhancing food comprising a fruit body (sexual generation and nonsexual generation), a mycelium and a metabolite fluid of an Isaria-type insect-raised fungus (Cordyceps Japonensis) as a main ingredient of the food.Type: GrantFiled: February 21, 1995Date of Patent: February 18, 1997Assignee: Kondoh et al.Inventors: Yoshikazu Kondoh, Nobuo Yahagi
-
Patent number: 5603960Abstract: The present invention describes a method for producing microparticles useful in the formulation of pharmaceutical compositions. The present invention further describes a method of immunizing a mammal against diseases comprising administering to a mammal an effective amount of antigen containing microparticles. In particular, the present invention describes a method of potentiating an immune response in a mammal comprising administering an effective amount of a pharmaceutical composition to a mammal. The present invention further describes a vaccine comprising a pharmaceutical composition containing said microparticles. An antigen delivery system comprising microparticles containing entrapped antigens is further described by the present invention. A pharmaceutical composition comprising microparticles and a pharmaceutical carrier is also provided.Type: GrantFiled: June 2, 1995Date of Patent: February 18, 1997Inventors: Derek T. O'Hagan, John P. McGee, Stanley S. Davis
-
Patent number: 5604209Abstract: Antiviral agents which comprises as active ingredients one or more 2',3'-dideoxyribonucleosides or phosphoric esters thereof and 6-benzyl-1-ethoxymethyl-5-substituted uracil derivative of the formula (I): ##STR1## wherein X is oxygen or sulfur atom; R.sup.1 is ethyl or isopropyl; R.sup.2 and R.sup.3 are independently hydrogen atom, C.sub.1 -C.sub.3 alkyl or halogen atom, which compounds can inhibit HIV reverse transcriptase through different mechanisms and are synergistic in combination.Type: GrantFiled: June 2, 1994Date of Patent: February 18, 1997Assignee: Mitsubishi Chemical CorporationInventors: Masaru Ubasawa, Satoshi Yuasa
-
Pharmaceutical composition of activity in the treatment of cognitive and/or neuroimmune dysfunctions
Patent number: 5601829Abstract: A pharmaceutical composition with beneficial effects in disorders which deal with cognitive, neurodegenerative and/or neuroimmune dysfunctions, especially the Alzheimer disease, characterized in that it comprises, as active ingredient, an isolated, natural hydrosoluble extract of the rhizome or leaves of Phlebodium decumanum, Polypodium aureum, Polypodium leucotomos, Polypodium vulgare, Polypodium trisereiale, Pteridium aquilinum, Dryopteris crassirhizoma and Cyathea taiwamiana, and the liposoluble fraction derivates of said extract, together with an acceptable pharmaceutical vehicle.Type: GrantFiled: May 3, 1995Date of Patent: February 11, 1997Assignee: Especialidades Farmaceuticas Centrum, S.A.Inventors: Eliseo Quintanilla Almagro, Joaquin Diaz Alperi -
Patent number: 5602109Abstract: An improved enteral nutritional formula containing ribo-nucleotide equivalents (RNA, mono-, di- and triphosphate nucleotides, nucleosides and adjuncts such as activated sugars) at a level of at least 10 mg/100 Kcal (kilocalorie) of formula is disclosed. The formula comprises carbohydrates, lipids, proteins, vitamins and minerals and four (4) ribo-nucleotide equivalents at specific levels and ratios. The invention also discloses novel methods of production and analytical techniques. This invention also provides a dietary formula that enhances the immune system and alleviates diarrhea.Type: GrantFiled: January 10, 1994Date of Patent: February 11, 1997Assignee: Abbott LaboratoriesInventors: Marc L. Masor, Milo D. Hilty
-
Patent number: 5599788Abstract: A method of producing recombinant transforming growth factor .beta.-induced H3 protein and the use of this protein to accelerate wound healing. H3 promoted adhesion of human dermal fibroblasts to tissue culture plastic. The protein is applied directly to a wound or is used to promote adhesion and spreading of dermal fibroblasts to a solid support such as a nylon mesh which is then applied to the wound. In addition, CHO cells expressing H3 inhibited tumor cell growth.Type: GrantFiled: July 1, 1994Date of Patent: February 4, 1997Assignee: Advanced Tissue SciencesInventors: Anthony F. Purchio, Richard LeBaron
-
Patent number: 5597807Abstract: Novel Quinoa saponin pharmaceutical compositions are disclosed. The compositions are useful as immunological adjuvants, to stimulate nonspecific immunity, as well as to enhance an immunological response to a selected antigen. The Quinoa saponin compositions can also be used to enhance mucosal absorption of a drug administered therewith.Type: GrantFiled: August 1, 1994Date of Patent: January 28, 1997Assignee: University of SaskatchewanInventors: Alberto Estrada, Mark J. Redmond, Bernard Laarveld
-
Patent number: 5591441Abstract: A non-specific host immune cell augmentation composition for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.Type: GrantFiled: February 16, 1994Date of Patent: January 7, 1997Assignee: Medical Sciences Research InstituteInventors: Anthony G. Gristina, Quentin N. Myrvik
-
Patent number: 5587364Abstract: Methods of treating inflammatory diseases in an animal by administering to the animal an effective amount of a polymeric acetylated mannan derivative of aloe origin.Type: GrantFiled: June 5, 1995Date of Patent: December 24, 1996Assignee: Carrington Laboratories, Inc.Inventors: Bill H. McAnalley, Robert H. Carpenter, Harley R. McDaniel